{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:18:50Z","timestamp":1792016330841,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.ygyno.2004.05.050","type":"journal-article","created":{"date-parts":[[2004,7,23]],"date-time":"2004-07-23T10:54:10Z","timestamp":1090580050000},"page":"719-724","source":"Crossref","is-referenced-by-count":18,"title":["Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer"],"prefix":"10.1016","volume":"94","author":[{"given":"John P.","family":"Micha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram H.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Rettenmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Mattison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheri","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie L.","family":"Birk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2004.05.050_BIB1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","article-title":"Cancer statistics 2001","volume":"51","author":"Greenlee","year":"2001","journal-title":"CA Cancer J. Clin."},{"issue":"1 Suppl. 1","key":"10.1016\/j.ygyno.2004.05.050_BIB2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/sonc.2002.31593","article-title":"Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma","volume":"29","author":"Hansen","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB3","first-page":"220a","article-title":"A phase I intra & interpatient dose ranging trial of gemcitabine, carboplatin and paclitaxel (GCP) in previously untreated patients with epithelial ovarian cancer, primary peritoneal malignancy, ovarian carcinosarcoma and fallopian tube carcinoma","volume":"20","author":"Poole","year":"2001","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0959-8049(96)00338-3","article-title":"Gemcitabine in ovarian cancer: an overview of safety and efficacy","volume":"33","author":"Kaufmann","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2004.05.050_BIB5","first-page":"72","article-title":"Interaction between cisplatin and gemcitabine in vitro and in vivo","volume":"22","author":"Peters","year":"1995","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB6","first-page":"356a","article-title":"Gemcitabine in combination with cisplatin in advanced ovarian cancers (AOC): a phase II study","volume":"17","author":"Krakowski","year":"1998","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB7","first-page":"357a","article-title":"Gemcitabine combined with cisplatin first line: a phase II study in patients with advanced epithelial ovarian cancer","volume":"17","author":"Nogue","year":"1998","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00001813-200209000-00009","article-title":"Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer","volume":"13","author":"Nogue","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ygyno.2004.05.050_BIB9","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","article-title":"Phase II study of gemcitabine (2\u2032,2\u2032-difluorodeoxycytidine) in previously treated ovarian cancer patients","volume":"86","author":"Lund","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","article-title":"Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel","volume":"63","author":"Shapiro","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB11","first-page":"367a","article-title":"A preliminary report of a phase 2 study of gemcitabine in women with platinum refractory mullerian (ovarian, fallopian tube and primary peritoneal) carcinomas","volume":"17","author":"Kudelka","year":"1998","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB12","first-page":"290a","article-title":"A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (EOC)","volume":"15","author":"Underhill","year":"1996","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"issue":"Suppl. 4","key":"10.1016\/j.ygyno.2004.05.050_BIB13","first-page":"31","article-title":"Gemcitabine, paclitaxel, and carboplatin for advanced non-small cell lung cancer","volume":"14","author":"Greco","year":"2000","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2004.05.050_BIB14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/gyno.1997.4916","article-title":"Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer","volume":"68","author":"Brown","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB15","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/1097-0142(19940815)74:4<1377::AID-CNCR2820740431>3.0.CO;2-U","article-title":"Paclitaxel administered by 1-hour infusion","volume":"74","author":"Hainsworth","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2004.05.050_BIB16","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-79-4-604","article-title":"Creatinine clearance: bedside estimate","volume":"79","author":"Jelliffe","year":"1973","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB18","series-title":"WHO handbook for reporting results for cancer treatment","year":"1979"},{"key":"10.1016\/j.ygyno.2004.05.050_BIB19","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","article-title":"Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels","volume":"19","author":"Rustin","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 9","key":"10.1016\/j.ygyno.2004.05.050_BIB20","first-page":"27","article-title":"The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer","volume":"25","author":"Rossel","year":"1998","journal-title":"Semin. Oncol."},{"issue":"Suppl. 4","key":"10.1016\/j.ygyno.2004.05.050_BIB21","first-page":"41","article-title":"Paclitaxel\/Carboplatin vs. Paclitaxel\/Gemcitabine in advanced non-small cell lung cancer","volume":"7","author":"Kosmidis","year":"2000","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2004.05.050_BIB22","first-page":"S2-31","article-title":"Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study","volume":"24","author":"Ten Bokkel Huinink","year":"1997","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB23","first-page":"479","article-title":"Phase 3 randomized trial of 12 versus 3 months of single agent paclitaxel in patients with advanced ovarian cancer who attained a clinically defined complete response to platinum\/paclitaxel-based chemotherapy. A Southwest Oncology Group and Gynecologic Oncology Group trial","volume":"84","author":"Markman","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.1998.4973","article-title":"A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II\u2013IV epithelial ovarian cancer following negative surgical assessment","volume":"69","author":"Barakat","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB25","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1200\/JCO.1997.15.5.1965","article-title":"Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting","volume":"15","author":"Gordon","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.050_BIB26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomized trial","volume":"360","author":"Ozols","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2004.05.050_BIB27","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0959-8049(02)00242-3","article-title":"Dose-dense cisplatin\/paclitaxel. A well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer","volume":"38","author":"de Jongh","year":"2002","journal-title":"Eur. J. Cancer"},{"issue":"1 Suppl. 1","key":"10.1016\/j.ygyno.2004.05.050_BIB28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/sonc.2002.31590","article-title":"The role of gemcitabine based doublets in the management of ovarian carcinoma","volume":"29","author":"Thigpen","year":"2002","journal-title":"Semin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804003816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804003816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T09:28:16Z","timestamp":1549358896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825804003816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0090825804003816"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2004.05.050","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}